Craig Kevin James, the Chief Medical Officer of AtaiBeckley Inc. (OTCQX: ATAI), completed the sale of 100,000 shares of common stock on March 20, 2026. The shares were sold at $3.55 each, producing proceeds of $355,000. That sale occurred while the stock was trading at $3.37, reflecting a 7.4% decline over the prior week despite an impressive 115% gain over the last 12 months.
Also on March 20, 2026, James exercised stock options to acquire a total of 100,000 shares of AtaiBeckley common stock. Those option exercises were split into two tranches - 76,224 shares at an exercise price of $1.18 per share and 23,776 shares at an exercise price of $1.50 per share - producing a combined exercise value recorded as $125,608.
The public sale of shares by James was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on December 19, 2025. The company’s recent market activity and insider transactions come amid notable corporate developments that include index inclusions and advancing clinical programs.
AtaiBeckley has been added to several benchmark indices - the S&P Total Market Index, the S&P Completion Index, and CRSP U.S. benchmark indices. These indices are reconstituted quarterly and serve as the basis for institutional index funds that, collectively, represent over $3 trillion in assets. Inclusion in these indices can affect passive demand for a company’s shares as index funds rebalance.
On the clinical front, AtaiBeckley published Phase 2a study results for BPL-003, a nasal spray intended to treat moderate-to-severe treatment-resistant depression, in the Journal of Psychopharmacology. The Phase 2a report covered 12 patients and used the Montgomery-Åsberg Depression Rating Scale to evaluate outcomes, with the authors describing the results as promising for the measured endpoints.
Separately, H.C. Wainwright reiterated a Buy rating for atai Life Sciences and set a price target of $25.00. The firm highlighted an ongoing, four-part Phase 2a program for BPL-003 and pointed to a sustained therapeutic effect from a single dose lasting up to 12 weeks in their commentary.
Atai Life Sciences also hosted a virtual investor day to outline the planned ReConnection Phase 3 pivotal program for BPL-003. According to the company’s schedule, those Phase 3 trials are expected to commence in the second quarter of 2026, with topline data anticipated in early 2029.
Investor-facing services have noted the stock’s price volatility. InvestingPro, which lists 12 additional exclusive tips for ATAI, characterizes the company’s share price as exhibiting volatile movements - a factor market participants watch when evaluating insider transactions and trading plans.
Note: The article reports transactions, index inclusions, published clinical data, and analyst commentary as disclosed. It does not offer investment advice.